Human Immunodeficiency Virus I Infection, Influenza, Human
Conditions
Brief summary
Investigators in the Division of Infectious Diseases are carrying out a study to determine if human immunodeficiency virus (HIV)-seropositive patients receiving the Seasonal Influenza vaccination develop an adequate antibody response. The study group will consist of individuals seen in the Infectious Diseases Clinic who are HIV-seropositive and receive the Seasonal Influenza vaccine.
Detailed description
This is a study to establish the immunologic response in HIV-seropositive individuals to the FDA approved seasonal influenza vaccine when it is available. HIV-seropositive individuals seen in the Infectious Diseases Clinic at George Washington University, Medical Faculty Associates and receive this vaccination, on label, as part of standard of care will be invited to participate. The study will require a 10-ml sample of whole blood to be drawn from each participant prior to the dose of the seasonal influenza vaccine and at 3 weeks after the vaccine dose and at 3 months after the vaccine dose. No additional samples are envisioned. Serum will be separated and will frozen and stored in the Clinical Trials Unit until all patient samples have been obtained. At that time the antibody levels to the vaccine antigens will be measured. Data that will be collected from the subject's medical record includes the following: * Age, gender, race * CD4 count * HIV viral load * History of prior influenza immunization including the 2009-2010 trivalent vaccine * HIV antiviral medication history Data that will be collected from the subject during participation in study * Antibody levels prior to vaccination * Dose date of the seasonal influenza vaccination * Antibody levels 3 weeks after the vaccination
Interventions
None listed
Sponsors
George Washington University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Males or female patients ages 18 or older * Diagnosis of HIV infection * No contraindications to being able to receive influenza vaccine by the treating physician * No acute active illness * Able to provide informed consent
Exclusion criteria
* Previous history of hypersensitivity reaction to influenza vaccine * Unable to return for follow-up blood draw
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in antibody levels | Pre-, 3 weeks post-, 3 months post- vaccine | The primary endpoint will be to measure the change from baseline in vaccine-strain specific antibody levels. Titers of \> or = 40 U will be considered protective and a \> 4-fold rise in antibody titer will be considered an adequate response in previously antibody-negative patients. Data from this study will assist in defining the efficacy of the influenza vaccine in the HIV-infected population and the ability of HIV-infected patients to generate an appropriate immune response, as well as maintain an appropriate response, to the influenza vaccine. |
Countries
United States
Outcome results
None listed